INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09969 INNOCARE

Market Closed 06-26 16:08:11

10.850

+0.070

+0.65%

High11.130	Low10.490	Vol10.38M
Open10.700	D1 Closing10.780	Amplitude5.94%
Mkt Cap19.15B	Tradable Cap16.21B	Total Shares1.76B
T/O112.53M	T/O Rate0.69%	Tradable Shares1.49B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"INNOCARE","latestPrice":10.85,"timestamp":1782461291011,"preClose":10.78,"halted":0,"volume":10377147,"delay":0,"changeRate":0.00649350649350652,"floatShares":1494000000,"shares":1764999999,"eps":0.38,"marketStatus":"Market Closed","change":0.07,"latestTime":"06-26 16:08:11","open":10.7,"high":11.13,"low":10.49,"amount":112526991,"amplitude":0.059369,"askPrice":10.85,"askSize":73000,"bidPrice":10.78,"bidSize":27000,"shortable":3,"etf":0,"ttmEps":0.469,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1782696600000},"marketStatusCode":7,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":10.78,"openAndCloseTimeList":[[1782437400000,1782446400000],[1782450000000,1782460800000]],"volumeRatio":1.4075670066487191,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"Innocare Pharma Limited","latestPrice":25.3,"timestamp":1782457200000,"preClose":25.88,"halted":0,"volume":12197900,"delay":0,"premium":"-62.80"}},"requestUrl":"/m/hq/s/09969/","defaultTab":"news","newsList":[{"id":"1136749555","title":"Innocare Pharma Issues 2.42 Million New Shares Under 2024 Equity Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1136749555","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136749555?lang=en_us&edition=fundamental","pubTime":"2026-06-26 17:19","pubTimestamp":1782465596,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (HKEX: 09969) has announced the issuance of new shares pursuant to its 2024 equity incentive plan.On June 26, 2026, the company issued 795,000 new shares to two directors as a...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK1161","CYB","MCNHmain","BK0239","CNHmain","BK1574","MUCmain","09969","UCmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645252940","title":"Extensive Orelabrutinib Data Across Regions Might Change The Case For Investing In InnoCare Pharma (SEHK:9969)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645252940","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645252940?lang=en_us&edition=fundamental","pubTime":"2026-06-22 17:22","pubTimestamp":1782120162,"startTime":"0","endTime":"0","summary":"In June 2026, InnoCare Pharma reported that over 40 clinical studies of its BTK inhibitor orelabrutinib were presented at the European Hematology Association Congress, highlighting consistent efficacy and safety across multiple blood cancers and patient populations in the United States, Europe, and China.\nBeyond confirming strong responses in chronic lymphocytic leukemia and marginal zone lymphoma, the data suggested orelabrutinib may offer a differentiated safety profile and meaningful...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/extensive-orelabrutinib-data-across-regions-might-change-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","BK1161","AIPO","CHAT","LU1883839398.USD","BK4585","BK1574","09969","ARTY","LU1880398554.USD","RF","LU1880398471.USD","AGIX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645809471","title":"InnoCare Pharma (SEHK:9969) Stock Could Be 45% Undervalued After EHA 2026 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2645809471","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645809471?lang=en_us&edition=fundamental","pubTime":"2026-06-21 13:24","pubTimestamp":1782019485,"startTime":"0","endTime":"0","summary":"Why InnoCare Pharma Stock Is In Focus After EHA 2026\nInnoCare Pharma (SEHK:9969) has drawn fresh attention after presenting data from more than 40 clinical studies of its BTK inhibitor orelabrutinib at the European Hematology Association 2026 Congress.\nThe company highlighted outcomes across several hematological cancers, including chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B cell lymphoma, and primary central nervous...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-could-be-45-undervalued-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/innocare-pharma-sehk9969-stock-could-be-45-undervalued-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100666683","title":"Innocare Pharma Shares Surge Over 5% on Positive Phase III Data for Tafasitamab Combo in Frontline DLBCL","url":"https://stock-news.laohu8.com/highlight/detail?id=1100666683","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100666683?lang=en_us&edition=fundamental","pubTime":"2026-06-18 11:00","pubTimestamp":1781751628,"startTime":"0","endTime":"0","summary":"Shares of Innocare Pharma Limited (ASX: 09969) rose more than 5% during the trading session. At the time of writing, the stock was up 3.29% to HK$10.69, with a turnover of approximately HK$43.05...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK1574","09969","BK4588","BK0239","BK4585","VXUS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149042368","title":"INNOCARE Issues 8 Million Restricted Shares Under Incentive Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1149042368","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149042368?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:06","pubTimestamp":1781611561,"startTime":"0","endTime":"0","summary":"INNOCARE (09969) has announced the initial grant under its 2026 RMB Share Incentive Plan. Following the close of trading today and the conclusion of its Annual General Meeting, the company has...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","BK1574","688428","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171222528","title":"InnoCare issues 8.00 million restricted shares (0.45% stake) in first tranche of 2026 RMB Share Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=1171222528","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171222528?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:05","pubTimestamp":1781611501,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Limited (InnoCare) has completed the first grant under its 2026 RMB Share Incentive Scheme, issuing 8.00 million restricted shares to 100 eligible employees after market close on 16...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132739434","title":"InnoCare Pharma: Shareholders Overwhelmingly Approve All 24 Resolutions at 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1132739434","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132739434?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:04","pubTimestamp":1781611499,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Limited reported that all 24 proposals tabled at its Annual General Meeting (AGM) on 16 June 2026 received the requisite shareholder support, with each ordinary resolution gaining...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145074084","title":"Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1145074084","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145074084?lang=en_us&edition=fundamental","pubTime":"2026-06-12 14:56","pubTimestamp":1781247396,"startTime":"0","endTime":"0","summary":"Innovative drug concept stocks are mostly trading higher. SKB BIO (06990) is up 8.62% at HK$428.4. REMEGEN (09995) has gained 8.11% to HK$75.3. INNOCARE (09969) rose 6.67% to HK$11.04. IMMUNOTECH-B...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","01276","LU2328871848.SGD","VXUS","06978","LU0359201885.HKD","BK1161","BK4588","LU2543165471.USD","LU0196878994.USD","BK1574","159992","LU1969619763.USD","LU1023057109.AUD","LU0359202008.SGD","09969","06990","BK1583","LU0359201612.USD","BK4585","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145822922","title":"Innocare Appoints Yuan Bei as Joint Company Secretary","url":"https://stock-news.laohu8.com/highlight/detail?id=1145822922","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145822922?lang=en_us&edition=fundamental","pubTime":"2026-06-05 18:38","pubTimestamp":1780655904,"startTime":"0","endTime":"0","summary":"Innocare (HKEX: 09969) has announced the appointment of Ms. Yuan Bei, the company's Senior Director of Investor Relations, as a Joint Company Secretary.The appointment will take effect from June 5,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1161","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640977761","title":"A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2640977761","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640977761?lang=en_us&edition=fundamental","pubTime":"2026-06-03 14:16","pubTimestamp":1780467404,"startTime":"0","endTime":"0","summary":"Recent performance and context\nInnoCare Pharma (SEHK:9969) has drawn attention after its share price closed at HK$11.26, with the stock down 2.3% over the past day and 3.7% over the past week.\nThat shorter term weakness sits alongside a decline of 18.6% over the past month and a year to date fall of 9.9%. Over a longer period, the stock is up 2.9% over the past 3 months and 2.0% over the past year.\nSee our latest analysis for InnoCare Pharma.\nRecent trading has been choppy, with the share...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09969","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639490386","title":"InnoCare Pharma Gets Acceptance for ITP New Drug Application; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639490386","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639490386?lang=en_us&edition=fundamental","pubTime":"2026-05-29 13:38","pubTimestamp":1780033123,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SHA:688428, HKG:9969) said China's drug regulator accepted the new drug application for orelabrutinib for treating primary immune thrombocytopenia (ITP), according to a Friday filing with the Shanghai bourse.Shares of the drugmaker rose 3% in recent trade on the Hong Kong bourse.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688428","09969","BK4199","ITP","BK1161","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136555407","title":"Innocare's New Drug Application for Orelabrutinib in ITP Accepted for Review by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1136555407","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136555407?lang=en_us&edition=fundamental","pubTime":"2026-05-28 16:29","pubTimestamp":1779956955,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (688428.SH) announced that the New Drug Application (NDA) for its self-developed Bruton's tyrosine kinase (BTK) inhibitor, orelabrutinib, intended for the treatment of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK1161","IPOS","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638465679","title":"InnoCare Pharma Wins Australia Approval for Lymphoma Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2638465679","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638465679?lang=en_us&edition=fundamental","pubTime":"2026-05-28 11:09","pubTimestamp":1779937762,"startTime":"0","endTime":"0","summary":"InnoCare Pharma  said Australia's Therapeutic Goods Administration approved orelabrutinib for the treatment of adult patients with relapsed or refractory mantle cell lymphoma, according to a Wednesday Hong Kong bourse filing.Shares of the pharmaceutical company fell by over 2% in late-morning trade on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IOZ.AU","EIGA.AU","XAO.AU","GEAR.AU","IMLC.AU","E200.AU","IIGF.AU","DACE.AU","XKO.AU","VAS.AU","BEAR.AU","VAP.AU","ZYAU.AU","OZR.AU","OZF.AU","SLF.AU","BK1574","BBOZ.AU","STW.AU","09969","GIVE.AU","IISV.AU","QFN.AU","QRE.AU","XJO.AU","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100302568","title":"Innocare Pharma's Orelabrutinib Receives Marketing Authorization from Australian TGA","url":"https://stock-news.laohu8.com/highlight/detail?id=1100302568","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100302568?lang=en_us&edition=fundamental","pubTime":"2026-05-27 16:32","pubTimestamp":1779870754,"startTime":"0","endTime":"0","summary":"Innocare Pharma Limited (688428.SH) announced that it has received notification that orelabrutinib (marketed as Yinuokai® and HIBRUKA®) has been granted marketing authorization by the Australian...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK1161","IPOS","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638251691","title":"InnoCare Pharma to Vest Over 2.4 Million Shares for 74 Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251691","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638251691?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:59","pubTimestamp":1779793189,"startTime":"0","endTime":"0","summary":"InnoCare Pharma (SHA:688428, HKG:9969) approved the vesting of shares under a stock incentive plan and the cancellation of granted but unvested shares, according to a Tuesday filing with the Shanghai ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688428","BK1161","BK1574","09969","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186054640","title":"Innocare Shares Surge Over 4% in Afternoon Trading Following Milestone in Novel Anti-Inflammatory Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1186054640","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186054640?lang=en_us&edition=fundamental","pubTime":"2026-05-21 14:08","pubTimestamp":1779343714,"startTime":"0","endTime":"0","summary":"Innocare (09969) saw its shares rise more than 4% in afternoon trading. At the time of writing, the stock was up 3.27% to HKD 12.32, with a turnover of approximately HKD 90.33 million. The increase...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","159992","BK4588","688428","BK4585","BK1574","BK0239","09969","VXUS","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635678612","title":"InnoCare Pharma Unit Doses First Patient in Autoimmune Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2635678612","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635678612?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:06","pubTimestamp":1778670400,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Ltd.  unit InnoCare Pharma Inc. dosed the first subject in a phase 1 trial of ICP-054 in China.Preclinical data shows the potential of ICP-054 to be a differentiated oral therapy for autoimmune and inflammatory diseases associated with dysregulated IL-17 signaling, according to a Wednesday Hong Kong bourse filing.The Hong Kong-listed drugmaker is developing the drug in partnership with Zenas BioPharma.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["09969","BK1574","BK0239","BK1161","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149280129","title":"InnoCare and Zenas BioPharma Dose First Subject in Phase 1 Study of Oral IL-17AA/AF Inhibitor ICP-054","url":"https://stock-news.laohu8.com/highlight/detail?id=1149280129","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149280129?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:03","pubTimestamp":1778670215,"startTime":"0","endTime":"0","summary":"InnoCare Pharma Limited (InnoCare) announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial evaluating ICP-054 (ZB021), a novel oral IL-17AA/AF inhibitor being...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185848254","title":"Innocare Announces First Patient Dosed in Phase 1 Trial for Oral IL-17 Inhibitor ICP-054 (ZB021)","url":"https://stock-news.laohu8.com/highlight/detail?id=1185848254","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185848254?lang=en_us&edition=fundamental","pubTime":"2026-05-13 18:50","pubTimestamp":1778669439,"startTime":"0","endTime":"0","summary":"Innocare (09969) announced that the first participant has been dosed in the Phase 1 clinical trial for ICP-054 (ZB021), a novel oral, potential best-in-class IL-17AA/AF inhibitor. ICP-054 is a new,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688428","BK1161","BK0239","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634640513","title":"A Look At InnoCare Pharma (SEHK:9969) Valuation After Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2634640513","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634640513?lang=en_us&edition=fundamental","pubTime":"2026-05-11 13:31","pubTimestamp":1778477471,"startTime":"0","endTime":"0","summary":"Recent performance snapshot\nInnoCare Pharma (SEHK:9969) has drawn investor attention after its shares closed at HK$13.51. The stock was down 3% over the past day and 11% over the past month, but up over the past 3 months.\nSee our latest analysis for InnoCare Pharma.\nThat recent pullback fits into a mixed picture, with the share price up 8.08% year to date and the 1-year total shareholder return at 40%, while the 5-year total shareholder return has been weaker.\nIf you are weighing what else...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9969/innocare-pharma-shares/news/a-look-at-innocare-pharma-sehk9969-valuation-after-recent-sh-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0766},{"period":"3month","weight":-0.1724},{"period":"6month","weight":-0.1724},{"period":"1year","weight":-0.1891},{"period":"ytd","weight":-0.1179}],"compareEarnings":[{"period":"1week","weight":-0.0524},{"period":"1month","weight":-0.1049},{"period":"3month","weight":-0.0914},{"period":"6month","weight":-0.1219},{"period":"1year","weight":-0.068},{"period":"ytd","weight":-0.1154}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal T cell function. The Company conducts its businesses in domestic and overseas markets.","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.714286,"avgChangeRate":0.101324},{"month":7,"riseRate":0.5,"avgChangeRate":0.039258},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.082108},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.024907},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"INNOCARE","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INNOCARE,09969,INNOCARE股票,INNOCARE股票老虎,INNOCARE股票老虎国际,INNOCARE行情,INNOCARE股票行情,INNOCARE股价,INNOCARE股市,INNOCARE股票价格,INNOCARE股票交易,INNOCARE股票购买,INNOCARE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INNOCARE(09969),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INNOCARE(09969) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}